metformin has been researched along with Tuberculosis in 31 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Accumulating evidence suggested that the use of metformin had more benefits for both prevention and treatment of tuberculosis (TB) than non-metformin use in patients with diabetes mellitus (DM); however, it remains to be fully elucidated on this topic." | 9.05 | Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis. ( He, JQ; Zhang, M, 2020) |
| "To assess the impact of metformin use on health-related quality of life (HRQoL) in tuberculosis (TB) patients who are presented with type 2 diabetes mellitus (T2DM)." | 8.02 | Impact of metformin therapy on health-related quality of life outcomes in tuberculosis patients with diabetes mellitus in India: A prospective study. ( Kapur, P; Khayyam, KU; Krishan, S; Mishra, R; Rai, PK; Sharma, M; Siddiqui, AN, 2021) |
| "The protective effect of metformin against active tuberculosis (TB) among TB close contacts is unknown." | 7.91 | Impact of metformin use among tuberculosis close contacts with diabetes mellitus in a nationwide cohort study. ( Chen, SM; Lee, CH; Lee, MC; Lee, MR; Wang, JY, 2019) |
| "The pharmacokinetic (PK) and clinical implications of combining metformin with rifampicin are relevant to increasing numbers of patients with diabetic tuberculosis (TB) across the world and are yet unclear." | 7.91 | Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. ( Aarnoutse, RE; Alisjahbana, B; Burger, DM; Koenderink, JB; Livia, R; Ruslami, R; Santoso, P; Soetedjo, N; Te Brake, LHM; van Crevel, R; van Ewijk-Beneken Kolmer, E; Yunivita, V, 2019) |
| "Metformin, the most widely administered diabetes drug, has been proposed as a candidate adjunctive host-directed therapy for tuberculosis, but little is known about its effects on human host responses to Mycobacterium tuberculosis." | 7.91 | Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects. ( Arts, RJW; Blok, B; Böhme, J; Chen, J; Cliff, JM; Dockrell, HM; Eckold, C; Koeken, VACM; Lachmandas, E; Marzuki, MB; Netea, MG; Newell, E; Ratter, J; Singhal, A; Smolders, EJ; Stienstra, R; Teng, KWW; Van Crevel, R; Van den Heuvel, C, 2019) |
| "Metformin is an oral anti-diabetic therapy (ADT) to manage type 2 diabetes mellitus (T2DM), and has been reported to have potential anti-tuberculosis (TB) effects." | 7.88 | Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes. ( Chen, TC; Chen, YH; Chong, IW; Lin, SY; Lu, PL; Tu, HP; Wang, WH, 2018) |
| "Metformin prescription was not related to a lower risk of LTBI (OR, 0." | 6.61 | Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review. ( Cao, S; Chen, F; Feng, X; Li, L; Wei, X; Xia, L; Yu, X, 2019) |
| "Metformin, which is an essential anti-diabetic drug, has been shown to exhibit anti-TB effects in patients with DM." | 5.62 | The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus. ( Heo, E; Jang, EJ; Kim, E; Lee, CH, 2021) |
| "Metformin remains the first choice of treatment for diabetes mellitus and has a potential protective effect against TB infection." | 5.62 | Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: A retrospective cohort study in a single teaching hospital. ( Fu, CP; Lee, CL; Li, YH; Lin, SY, 2021) |
| "Comorbid type 2 diabetes poses a great challenge to the global control of tuberculosis." | 5.56 | Disparate Effects of Metformin on Mycobacterium tuberculosis Infection in Diabetic and Nondiabetic Mice. ( Govan, B; Hansen, K; Henning, L; Ketheesan, N; Kupz, A; Miranda-Hernandez, S; Rush, CM; Sathkumara, HD, 2020) |
| "Metformin (MET) is a potential combination drug to elevate anti-TB efficacy." | 5.51 | Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study. ( Ali, M; Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI, 2019) |
| "The global type 2 diabetes mellitus (DM) epidemic threatens progress made in reducing tuberculosis (TB)-related mortality worldwide." | 5.48 | Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. ( Degner, NR; Golub, JE; Karakousis, PC; Wang, JY, 2018) |
| "Accumulating evidence suggested that the use of metformin had more benefits for both prevention and treatment of tuberculosis (TB) than non-metformin use in patients with diabetes mellitus (DM); however, it remains to be fully elucidated on this topic." | 5.05 | Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis. ( He, JQ; Zhang, M, 2020) |
| "To assess the impact of metformin use on health-related quality of life (HRQoL) in tuberculosis (TB) patients who are presented with type 2 diabetes mellitus (T2DM)." | 4.02 | Impact of metformin therapy on health-related quality of life outcomes in tuberculosis patients with diabetes mellitus in India: A prospective study. ( Kapur, P; Khayyam, KU; Krishan, S; Mishra, R; Rai, PK; Sharma, M; Siddiqui, AN, 2021) |
| "Patients with type 2 diabetes (T2D) have a lower risk of Mycobacterium tuberculosis infection, progression from infection to tuberculosis (TB) disease, TB morality and TB recurrence, when being treated with metformin." | 3.96 | Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits. ( Ackart, D; Basaraba, R; Böhme, J; Frenkel, JH; Kornfeld, H; Lachmandas, E; Larbi, A; Lee, A; Lee, B; Li, S; Lum, J; Martinez, N; Marzuki, M; Netea, MG; Newell, E; Ng, TP; Shihui, F; Singhal, A; Tizazu, AM; Todd, A; van Crevel, R, 2020) |
| "The protective effect of metformin against active tuberculosis (TB) among TB close contacts is unknown." | 3.91 | Impact of metformin use among tuberculosis close contacts with diabetes mellitus in a nationwide cohort study. ( Chen, SM; Lee, CH; Lee, MC; Lee, MR; Wang, JY, 2019) |
| "The pharmacokinetic (PK) and clinical implications of combining metformin with rifampicin are relevant to increasing numbers of patients with diabetic tuberculosis (TB) across the world and are yet unclear." | 3.91 | Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. ( Aarnoutse, RE; Alisjahbana, B; Burger, DM; Koenderink, JB; Livia, R; Ruslami, R; Santoso, P; Soetedjo, N; Te Brake, LHM; van Crevel, R; van Ewijk-Beneken Kolmer, E; Yunivita, V, 2019) |
| "Metformin, the most widely administered diabetes drug, has been proposed as a candidate adjunctive host-directed therapy for tuberculosis, but little is known about its effects on human host responses to Mycobacterium tuberculosis." | 3.91 | Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects. ( Arts, RJW; Blok, B; Böhme, J; Chen, J; Cliff, JM; Dockrell, HM; Eckold, C; Koeken, VACM; Lachmandas, E; Marzuki, MB; Netea, MG; Newell, E; Ratter, J; Singhal, A; Smolders, EJ; Stienstra, R; Teng, KWW; Van Crevel, R; Van den Heuvel, C, 2019) |
| "Metformin is an oral anti-diabetic therapy (ADT) to manage type 2 diabetes mellitus (T2DM), and has been reported to have potential anti-tuberculosis (TB) effects." | 3.88 | Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes. ( Chen, TC; Chen, YH; Chong, IW; Lin, SY; Lu, PL; Tu, HP; Wang, WH, 2018) |
| "Metformin prescription was not related to a lower risk of LTBI (OR, 0." | 2.61 | Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review. ( Cao, S; Chen, F; Feng, X; Li, L; Wei, X; Xia, L; Yu, X, 2019) |
| " Although no studies have been performed, anti-tuberculosis treatment may also have to be prolonged or intensified in terms of regimen or drug dosage if DM is present." | 2.58 | Clinical management of combined tuberculosis and diabetes. ( Harries, AD; Hill, PC; Koesoemadinata, R; van Crevel, R, 2018) |
| "Metformin, which is an essential anti-diabetic drug, has been shown to exhibit anti-TB effects in patients with DM." | 1.62 | The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus. ( Heo, E; Jang, EJ; Kim, E; Lee, CH, 2021) |
| "Metformin remains the first choice of treatment for diabetes mellitus and has a potential protective effect against TB infection." | 1.62 | Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: A retrospective cohort study in a single teaching hospital. ( Fu, CP; Lee, CL; Li, YH; Lin, SY, 2021) |
| "Comorbid type 2 diabetes poses a great challenge to the global control of tuberculosis." | 1.56 | Disparate Effects of Metformin on Mycobacterium tuberculosis Infection in Diabetic and Nondiabetic Mice. ( Govan, B; Hansen, K; Henning, L; Ketheesan, N; Kupz, A; Miranda-Hernandez, S; Rush, CM; Sathkumara, HD, 2020) |
| "Metformin (MET) is a potential combination drug to elevate anti-TB efficacy." | 1.51 | Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study. ( Ali, M; Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI, 2019) |
| "The global type 2 diabetes mellitus (DM) epidemic threatens progress made in reducing tuberculosis (TB)-related mortality worldwide." | 1.48 | Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. ( Degner, NR; Golub, JE; Karakousis, PC; Wang, JY, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (58.06) | 24.3611 |
| 2020's | 13 (41.94) | 2.80 |
| Authors | Studies |
|---|---|
| Heo, E | 1 |
| Kim, E | 1 |
| Jang, EJ | 1 |
| Lee, CH | 2 |
| Roca, FJ | 1 |
| Whitworth, LJ | 1 |
| Prag, HA | 1 |
| Murphy, MP | 1 |
| Ramakrishnan, L | 1 |
| Mehta, K | 1 |
| Guo, T | 1 |
| Wallis, RS | 1 |
| van der Graaf, PH | 1 |
| van Hasselt, JGC | 1 |
| Singh, S | 1 |
| Allwood, BW | 1 |
| Chiyaka, TL | 1 |
| Kleyhans, L | 1 |
| Naidoo, CC | 1 |
| Moodley, S | 1 |
| Theron, G | 1 |
| Segal, LN | 1 |
| Wang, Y | 1 |
| Zhou, Y | 1 |
| Chen, L | 1 |
| Cheng, Y | 1 |
| Lai, H | 1 |
| Lyu, M | 1 |
| Zeng, J | 1 |
| Zhang, Y | 2 |
| Feng, P | 1 |
| Ying, B | 1 |
| Mary Rebecca, Y | 1 |
| Sudha, V | 1 |
| Bharathiraja, T | 1 |
| Kannan, T | 1 |
| Lavanya, J | 1 |
| Hemanth Kumar, AK | 1 |
| Yu, X | 1 |
| Li, L | 1 |
| Xia, L | 1 |
| Feng, X | 1 |
| Chen, F | 1 |
| Cao, S | 1 |
| Wei, X | 1 |
| Lee, MC | 1 |
| Lee, MR | 1 |
| Wang, JY | 2 |
| Chen, SM | 1 |
| Zhang, M | 1 |
| He, JQ | 1 |
| Tsenova, L | 2 |
| Singhal, A | 4 |
| Sathkumara, HD | 1 |
| Hansen, K | 1 |
| Miranda-Hernandez, S | 1 |
| Govan, B | 1 |
| Rush, CM | 1 |
| Henning, L | 1 |
| Ketheesan, N | 1 |
| Kupz, A | 1 |
| Böhme, J | 2 |
| Martinez, N | 1 |
| Li, S | 1 |
| Lee, A | 1 |
| Marzuki, M | 1 |
| Tizazu, AM | 1 |
| Ackart, D | 1 |
| Frenkel, JH | 1 |
| Todd, A | 1 |
| Lachmandas, E | 2 |
| Lum, J | 1 |
| Shihui, F | 1 |
| Ng, TP | 1 |
| Lee, B | 1 |
| Larbi, A | 1 |
| Netea, MG | 2 |
| Basaraba, R | 1 |
| van Crevel, R | 4 |
| Newell, E | 2 |
| Kornfeld, H | 3 |
| Mishra, R | 1 |
| Krishan, S | 1 |
| Siddiqui, AN | 1 |
| Kapur, P | 1 |
| Khayyam, KU | 1 |
| Rai, PK | 1 |
| Sharma, M | 1 |
| Fu, CP | 1 |
| Lee, CL | 1 |
| Li, YH | 1 |
| Lin, SY | 2 |
| Liu, Q | 1 |
| You, N | 1 |
| Pan, H | 1 |
| Shen, Y | 1 |
| Lu, P | 1 |
| Wang, J | 1 |
| Lu, W | 1 |
| Zhu, L | 1 |
| Martinez, L | 1 |
| Degner, NR | 1 |
| Golub, JE | 1 |
| Karakousis, PC | 1 |
| Tu, HP | 1 |
| Lu, PL | 1 |
| Chen, TC | 1 |
| Wang, WH | 1 |
| Chong, IW | 1 |
| Chen, YH | 1 |
| Leung, CC | 1 |
| Kumar, NP | 2 |
| Moideen, K | 2 |
| Viswanathan, V | 2 |
| Shruthi, BS | 2 |
| Sivakumar, S | 2 |
| Menon, PA | 1 |
| Babu, S | 2 |
| Te Brake, LHM | 1 |
| Yunivita, V | 1 |
| Livia, R | 1 |
| Soetedjo, N | 1 |
| van Ewijk-Beneken Kolmer, E | 1 |
| Koenderink, JB | 1 |
| Burger, DM | 1 |
| Santoso, P | 1 |
| Alisjahbana, B | 1 |
| Aarnoutse, RE | 1 |
| Ruslami, R | 1 |
| Bhootra, Y | 1 |
| Nancy, A | 1 |
| Natarajan, M | 1 |
| Koesoemadinata, R | 1 |
| Hill, PC | 1 |
| Harries, AD | 1 |
| Eckold, C | 1 |
| Koeken, VACM | 1 |
| Marzuki, MB | 1 |
| Blok, B | 1 |
| Arts, RJW | 1 |
| Chen, J | 2 |
| Teng, KWW | 1 |
| Ratter, J | 1 |
| Smolders, EJ | 1 |
| Van den Heuvel, C | 1 |
| Stienstra, R | 1 |
| Dockrell, HM | 1 |
| Cliff, JM | 1 |
| Novita, BD | 1 |
| Ali, M | 1 |
| Pranoto, A | 1 |
| Soediono, EI | 1 |
| Mertaniasih, NM | 1 |
| Yew, WW | 1 |
| Chang, KC | 1 |
| Chan, DP | 1 |
| Oglesby, W | 1 |
| Kara, AM | 1 |
| Granados, H | 1 |
| Cervantes, JL | 1 |
| Jie, L | 1 |
| Kumar, P | 1 |
| Hong, GS | 1 |
| Leow, MK | 1 |
| Paleja, B | 1 |
| Kurepina, N | 1 |
| Zolezzi, F | 1 |
| Kreiswirth, B | 1 |
| Poidinger, M | 1 |
| Chee, C | 1 |
| Kaplan, G | 1 |
| Wang, YT | 1 |
| De Libero, G | 1 |
| Vashisht, R | 1 |
| Brahmachari, SK | 1 |
| Bloom, BE | 1 |
| Kalra, S | 1 |
| Atreja, A | 1 |
| Restrepo, BI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis: A Randomized Controlled Trial[NCT05215990] | Phase 1/Phase 2 | 80 participants (Anticipated) | Interventional | 2022-01-15 | Recruiting | ||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for metformin and Tuberculosis
| Article | Year |
|---|---|
Immunologic and imaging signatures in post tuberculosis lung disease.
Topics: Biomarkers; Collagen; Complex Mixtures; Cytokines; Doxycycline; Humans; Hydroxymethylglutaryl-CoA Re | 2022 |
Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review.
Topics: Antitubercular Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Odds Ratio | 2019 |
Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Incidence; Metformin; Tuberculosis | 2020 |
Effects of host-directed therapies on the pathology of tuberculosis.
Topics: Host-Pathogen Interactions; Humans; Hypoxia; Metformin; Mycobacterium tuberculosis; Neutrophils; Tub | 2020 |
Clinical management of combined tuberculosis and diabetes.
Topics: Antitubercular Agents; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Me | 2018 |
Metformin as a host-directed therapeutic in tuberculosis: Is there a promise?
Topics: Animals; Antitubercular Agents; Autophagy; Drug Interactions; Drug Therapy, Combination; Forecasting | 2019 |
Metformin in tuberculosis: beyond control of hyperglycemia.
Topics: Antitubercular Agents; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Metfor | 2019 |
The trials and tribulations of repurposing metformin and other generic drugs for tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Repositioning; Drugs, Generic; Humans; Hypoglycemic Agents; Met | 2016 |
Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients.
Topics: Antitubercular Agents; Diabetes Mellitus, Type 2; Host-Pathogen Interactions; Humans; Hypoglycemic A | 2016 |
22 other studies available for metformin and Tuberculosis
| Article | Year |
|---|---|
The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus.
Topics: Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female | 2021 |
Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport.
Topics: Animals; Citric Acid Cycle; Electron Transport; Electron Transport Complex I; Humans; Macrophages; M | 2022 |
Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy.
Topics: Animals; Anti-Bacterial Agents; Autophagy; Humans; Metformin; Mice; Mycobacterium tuberculosis; Netw | 2022 |
Metformin promotes smear conversion in tuberculosis-diabetes comorbidity and construction of prediction models.
Topics: Comorbidity; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Retrospective Studies; Tuber | 2022 |
Urinary excretion of metformin in diabetic patients with and without tuberculosis.
Topics: Antitubercular Agents; Diabetes Mellitus; Humans; India; Isoniazid; Metformin; Pyrazinamide; Tubercu | 2023 |
Impact of metformin use among tuberculosis close contacts with diabetes mellitus in a nationwide cohort study.
Topics: Adult; Aged; Comorbidity; Databases, Factual; Diabetes Mellitus; Female; Follow-Up Studies; Humans; | 2019 |
Disparate Effects of Metformin on Mycobacterium tuberculosis Infection in Diabetic and Nondiabetic Mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Metformin; | 2020 |
Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits.
Topics: Animals; BCG Vaccine; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Type 2; Female; Guinea Pigs; Hu | 2020 |
Impact of metformin therapy on health-related quality of life outcomes in tuberculosis patients with diabetes mellitus in India: A prospective study.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Prospec | 2021 |
Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: A retrospective cohort study in a single teaching hospital.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus; Female; Follow-Up Studies; Glomerular Filtration | 2021 |
Glycemic Trajectories and Treatment Outcomes of Patients with Newly Diagnosed Tuberculosis: A Prospective Study in Eastern China.
Topics: Adult; Antitubercular Agents; Blood Glucose; China; Cohort Studies; Diabetes Mellitus; Female; Human | 2021 |
Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2018 |
Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2018 |
Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2018 |
Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2018 |
Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes.
Topics: Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I | 2018 |
Repurposing metformin to prevent and treat tuberculosis.
Topics: Antitubercular Agents; Diabetes Mellitus, Type 2; Humans; Metformin; Risk; Tuberculosis | 2018 |
Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment.
Topics: Antitubercular Agents; Comorbidity; Diabetes Complications; Diabetes Mellitus; Humans; Matrix Metall | 2018 |
Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Blood Glucose; Cohort Studies; Diabetes Mellit | 2019 |
Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co-morbidity.
Topics: Adult; Aged; Biomarkers; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Mi | 2019 |
Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects.
Topics: Cell Proliferation; Down-Regulation; Healthy Volunteers; Host-Pathogen Interactions; Humans; Hypogly | 2019 |
Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study.
Topics: Adult; Antitubercular Agents; Autophagy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Etham | 2019 |
Metformin as adjunct antituberculosis therapy.
Topics: Humans; Metformin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Reactive Oxygen Species; | 2014 |
Metformin as adjunct antituberculosis therapy.
Topics: Humans; Metformin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Reactive Oxygen Species; | 2014 |
Metformin as adjunct antituberculosis therapy.
Topics: Humans; Metformin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Reactive Oxygen Species; | 2014 |
Metformin as adjunct antituberculosis therapy.
Topics: Humans; Metformin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Reactive Oxygen Species; | 2014 |
Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Humans; Metformin; Tubercul | 2015 |
Diabetic tuberculosis.
Topics: Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; I | 2016 |